Attenuating inflammation by inhibition of p38 MAP-kinase does not reduce CV endpoints in LATITUDE TIMI-60 - PACE-CME

Attenuating inflammation by inhibition of p MAPkinase does not reduce CV endpoints in LATITUDE TIMI

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Finerenone does not alter vascular stiffness in patients with T2D and CKD
Finerenone does not alter vascular stiffness in patients with T2D and CKD
ESC Heart Failure 2025
Finerenone does not alter vascular stiffness in patients with T2D and CKD
- Atsushi Tanaka, MD, PhD
Exciting times to address residual inflammatory risk
Exciting times to address residual inflammatory risk
EAS 2024
Exciting times to address residual inflammatory risk
- Peter Libby, MD
Anti-inflammatory therapies for CVD risk prevention
Anti-inflammatory therapies for CVD risk prevention
EAS 2024
Anti-inflammatory therapies for CVD risk prevention
- Ulrich Laufs, MD, PhD
The role of inflammation in atherosclerosis
The role of inflammation in atherosclerosis
Inflammation
The role of inflammation in atherosclerosis
- Peter Libby, MD